Cytomegalovirus (CMV) Retinitis

Cytomegalovirus (CMV) retinitis is a severe viral infection of the retina – the light‑sensing tissue at the back of the eye. CMV belongs to the herpes‑virus family. In most healthy people it hides quietly in body cells after the first infection, but when your immune defences drop very low the virus “wakes up,” travels through the bloodstream, and attacks the retina. The result is inflammation, cell death, bleeding, and scarring that can steal vision permanently if treatment is delayed. CMV retinitis was once “the most common cause of blindness in people living with AIDS,” and it still threatens anyone whose immune system is badly weakened by HIV, cancer chemotherapy, organ‑transplant medicines, or similar conditions. EyeWiki

Cytomegalovirus (CMV) retinitis is an infection of the light‑sensing layer of the eye (the retina) caused by human cytomegalovirus, a member of the herpes‑virus family. In people whose immune system is healthy, CMV usually stays dormant. When immunity collapses – for example with advanced HIV, following bone‑marrow or solid‑organ transplant, or while taking strong chemotherapy or long‑term steroids – the virus reactivates, travels through the bloodstream, and attacks retinal tissue. The result is progressive retinal cell death, necrosis, and scarring that can steal central and peripheral vision, sometimes within weeks if left untreated. Modern antiretroviral therapy (ART) has sharply reduced the incidence in HIV, yet CMV retinitis remains the leading infectious cause of blindness in immunocompromised adults worldwide EyeWiki.

Pathologically, CMV invades retinal vascular endothelial cells and retinal pigment epithelium (RPE). Viral replication triggers cell lysis and an intense local inflammatory reaction. As the lesion enlarges it leaves a pale, “pizza‑pie” scar with active, fluffy white borders. Untreated, the infection can spread 750 μm a day, cross the optic nerve, or cause rhegmatogenous retinal detachment.

Think of the retina as a delicate film lining the inside of a camera. CMV retinitis punches holes in that film. The virus directly kills retinal cells; the body’s own immune reaction adds swelling and leakage; tiny retinal blood vessels break and bleed. On a doctor’s exam the damage first pops up in the far edge of the retina and then creeps inward in a wave that looks like “pizza pie” – pale patches of dying tissue peppered with red hemorrhages. Without antiviral medicine this wave can cross the central retina in weeks, wipe out the sharp‑vision area (the macula), and even peel the retina off the eye wall (retinal detachment). Because early damage sits in the retinal periphery, many patients notice no problem until the disease is dangerously close to the centre.

Main types

1. Fulminant or Edematous type – Fast‑moving “pizza‑pie” lesions with lots of bleeding and swelling.

2. Indolent (granular) type – Slower, grainy yellow‑white spots with minimal bleeding; often seen in patients already taking some antivirals or with slightly stronger immunity.

3. Perivascular / Frosted‑branch angiitis type – White, fluffy plaques wrap around blood vessels like frost; vision can drop quickly when vessels close or leak.

4. Zone 1‑threatening type – Any pattern that reaches the macula or optic‑nerve head; this zone is critical for reading, driving, and colour vision, so urgency is extreme. PMCFrontiers

---

Causes

1. Advanced HIV infection (CD4 < 50 cells/µL) – The classic trigger; the virus revives when white‑cell guards are too few to keep it silent.

2. Solid‑organ transplantation – High‑dose immunosuppressive drugs (e.g., tacrolimus, mycophenolate) lower viral defence.

3. Stem‑cell or bone‑marrow transplant – Intensive chemotherapy and graft‑versus‑host prophylaxis leave long immune gaps.

4. Systemic steroids – Prolonged, high‑dose prednisone weakens both cellular and antibody immunity.

5. Biologic agents (e.g., infliximab, adalimumab) – These modern arthritis and IBD drugs dampen tumour‑necrosis factor or interleukins that normally help crush CMV.

6. Chemotherapy for blood cancers – Regimens for leukaemia or lymphoma decimate the very T‑cells that control CMV.

7. Primary combined immunodeficiency syndromes – Rare genetic errors leave children without functional T‑cells.

8. Congenital CMV infection – Babies infected in the womb may harbour active virus that later targets the eye.

9. Chronic renal failure requiring dialysis – Uraemia and repeated blood exposure modulate immunity.

10. Poorly controlled diabetes mellitus – Microvascular damage and altered white‑cell function reduce retinal resistance.

11. Malnutrition (severe protein‑calorie deficiency) – The body cannot build enough immune proteins.

12. Age‑related immunosenescence – Very elderly people sometimes reactivate CMV as T‑cell numbers fall.

13. Long‑term broad‑spectrum antibiotics – By disturbing gut flora, they blunt parts of the immune response.

14. Concurrent systemic CMV disease (e.g., colitis, pneumonitis) – A high viral load in blood makes seeding of the retina more likely.

15. Intense psychological stress / critical illness – Stress hormones temporarily suppress cell‑mediated immunity, tipping the balance in favour of reactivation.

---

Common symptoms

1. Floaters – Little cobwebs or dots drifting across vision as bits of inflamed tissue and blood float in the eye gel. Cleveland Clinic

2. Blurred vision – The retina’s photo‑receptors can’t fire correctly when overrun by viral inflammation.

3. Flashing lights (photopsia) – Irritated retina misfires, sending false light signals to the brain.

4. Painless progressive vision loss – Because the retina lacks pain fibres, large areas may die silently.

5. Blind spots (scotomas) – When an area of retina is destroyed, the matching part of the visual field goes dark.

6. Loss of side vision – Peripheral lesions first eat away the outer visual field.

7. Difficulty seeing colours – Damage to the macula or optic nerve alters colour perception.

8. Distortion (metamorphopsia) – Swelling near the macula can bend straight lines.

9. Sudden curtain‑like shadow – A sign of retinal detachment; emergency care is needed.

10. Seeing nothing from the affected eye – In end‑stage disease the entire retina may be degraded or detached. Frontiers

---

Diagnostic tests

A. Physical‑exam based tests

1. Visual‑acuity chart (Snellen or ETDRS)
   The patient reads letters at a set distance. Any drop from their previous best refraction hints at macular involvement. Easy, cheap, and repeatable at every visit.

2. Pupil reflex assessment
   A bright torch swings between the two eyes. A sluggish or “reverse” pupil reaction (afferent pupillary defect) suggests large retinal or optic‑nerve damage in the CMV‑affected eye.

3. Confrontation visual‑field test
   The doctor wiggles fingers in different directions while the patient fixes on their nose. Missing fingers signals peripheral retinal loss typical of early CMV activity.

 B. Manual ophthalmic tests

4. Indirect ophthalmoscopy with scleral depression
   Wearing a head‑lamp, the ophthalmologist uses a hand‑held lens to scan the full retina. Gentle press on the eye’s white wall brings the extreme periphery into view, crucial because CMV lesions often hide there first.

5. Amsler grid
   A simple square grid patients hold at reading distance. Wavy, missing, or blurry lines raise suspicion that CMV has crept into the macula. Self‑monitoring daily helps catch progression fast.

C. Laboratory / pathological tests

6. Quantitative CMV PCR in blood
   Measures viral DNA copies per millilitre. A high load during vision changes strengthens the diagnosis and helps track treatment response. Frontiers

7. Aqueous or vitreous fluid CMV PCR
   A tiny tap of eye fluid gives near‑perfect confirmation, especially when the retinal view is hazy or atypical.

8. CD4+ T‑cell count
   Numbers below 50–100 cells/µL signal extreme risk; rising counts under antiretroviral therapy predict better control and may guide when to stop intravitreal antivirals.

9. Complete blood count (CBC)
   Detects anaemia or neutropenia from ganciclovir toxicity and reveals general bone‑marrow health before antiviral therapy.

10. Liver‑function panel
    Baseline enzymes are needed because oral valganciclovir or foscarnet can stress the liver; sudden rises may force dose changes.

11. Serum creatinine and eGFR
    Essential because many antivirals exit via the kidneys; reduced filtration demands lower dosing to prevent side‑effects.

D. Electrodiagnostic tests

12. Full‑field Electroretinography (ERG)
    The patient’s dilated eye is flashed with light; electrodes pick up electrical responses from retinal cells. Deeper, flatter‑than‑normal waves hint that CMV has silently damaged retina beyond what is visible.

13. Visual‑Evoked Potential (VEP)
    Scalp electrodes record the brain’s response to checkerboard stimuli. Slower or smaller peaks show downstream optic‑pathway impairment when CMV or subsequent detachment reaches the nerve head.

 E. Imaging tests

14. Colour fundus photography
    High‑resolution pictures document the size and pattern of lesions; serial shots prove whether treatment is working or the disease is advancing.

15. Optical Coherence Tomography (OCT)
    A laser scanner produces cross‑section “microscope slices.” Doctors spot retinal thinning, swelling, or early detachment long before symptoms worsen.

16. Fundus fluorescein angiography (FFA)
    A fluorescent dye circulates through retinal vessels. Leaky or blocked vessels light up, mapping areas starved of blood where CMV sits.

17. Indocyanine‑green angiography (ICGA)
    Uses a different dye that shows deeper choroidal circulation, helpful if CMV masquerades as choroiditis in transplant patients.

18. Optical Coherence Tomography Angiography (OCTA)
    A dye‑free scan that visualises blood flow in retinal capillaries; early flow voids can alert clinicians before structural OCT shows damage.

19. B‑scan ocular ultrasound
    When cloudy cornea or vitreous haemorrhage blocks the view, ultrasound detects retinal detachment or thick inflammatory membranes.

20. Orbital MRI
    Rarely needed, but if other opportunistic infections (toxoplasmosis, lymphoma) are possible, MRI distinguishes deeper eye or brain lesions and informs combined treatment. PubMed

Non‑Pharmacological Treatments

Supportive care does not kill CMV directly, but it protects residual vision, improves daily functioning, and complements antiviral drugs.

1. Guided Saccadic Eye‑Movement Training (E) – Short, therapist‑led drills where you quickly shift gaze between fixed targets. Purpose: strengthens remaining peripheral vision. Mechanism: recruits healthy retinal zones to compensate for scotomas and accelerates visual‑search speed.

2. Contrast‑Sensitivity Exercise (E) – Reading letters of progressively lower contrast under controlled lighting. Purpose: boosts detection of faint objects. Mechanism: trains the brain’s visual cortex to amplify low‑contrast signals that slip through damaged retina.

3. Peripheral Field Expansion Scanning (E) – Clock‑face scanning routines using wall charts. Purpose: reduces bumping into obstacles. Mechanism: conditions vestibulo‑ocular reflexes to sweep a broader arc, mapping peripheral blind spots.

4. Text‑Magnifier Endurance Sets (E) – Daily 10‑minute reading with hand‑held or digital magnifiers at graded font sizes. Purpose: sustains near‑vision stamina. Mechanism: repetitive accommodation and convergence improve oculomotor endurance.

5. Posture & Neck‑Alignment Drills (E) – Simple chin‑tuck and shoulder‑roll sequences. Purpose: prevent neck strain when tilting to use vision out of scarred central fields. Mechanism: increases cervical proprioception and blood flow to ocular muscles.

6. Mobility Cane Circuit Training (E) – Obstacle‑course practice with an orientation‑and‑mobility (O&M) specialist. Purpose: safe navigation outdoors. Mechanism: converts tactile feedback into spatial memory maps, bypassing visual deficits.

7. Adaptive Yoga for Low Vision (M) – Slow, balance‑centred poses with verbal cues. Purpose: stabilises gait and reduces fall risk. Mechanism: enhances vestibular‑somatosensory integration, mitigating uncertain footing due to field cuts.

8. Mindfulness‑Based Stress Reduction (MBSR) (M) – Guided breathing, body‑scan, and non‑judgemental attention exercises for 20 min/day. Purpose: lowers anxiety linked to sight loss. Mechanism: dampens amygdala activity, which otherwise heightens cortisol and systemic inflammation.

9. Progressive Muscle Relaxation (M) – Sequential tensing and releasing of muscle groups. Purpose: eases chronic eye‑strain headaches. Mechanism: breaks the sympathetic‑nervous hyper‑tone loop that constricts periorbital blood flow.

10. Audio‑Guided Imagery (M) – Recorded descriptions of calming scenes. Purpose: counters visual‑hallucination anxiety (Charles Bonnet syndrome). Mechanism: recruits auditory and limbic pathways, reducing erroneous firing in visual association cortex.

11. Tai Chi for Vision Impairment (M) – 24‑form routine adapted with larger arm arcs. Purpose: improves balance. Mechanism: slow weight shifts train proprioceptors and strengthen lower‑limb muscles needed for uneven terrain.

12. Acupuncture Around Periorbital Points (M) – Use of points BL‑1, GB‑14, Taiyang. Purpose: anecdotal relief of eye pain, though evidence is limited. Mechanism: may modulate trigeminal‑vascular input and retinal microcirculation.

13. Low‑Vision Aid Coaching (S) – Teaching smartphone screen‑reader gestures and high‑contrast settings. Purpose: maximises residual vision in daily tasks. Mechanism: off‑loads decoding to auditory channels.

14. Digital Medication‑Reminder Apps (S) – Phone alarms that pop up pill photos. Purpose: boosts antiviral adherence. Mechanism: behavioural cueing fills lapses in prospective memory worsened by stress.

15. Lighting‑Optimization Workshops (S) – Relocating lamps, adding task lights, reducing glare film. Purpose: enhances reading contrast. Mechanism: raises retinal illumination in surviving photoreceptors without phototoxic peaks.

16. Peer‑Support Groups (S) – Weekly virtual or in‑person meetings. Purpose: emotional coping and information exchange. Mechanism: shared narrative lowers perceived isolation, reducing depressive cytokine cascades.

17. Vision‑Focused Nutritional Counselling (S) – Dietitian‑led sessions on antioxidant‑rich foods. Purpose: complements supplement plan. Mechanism: supplies lutein, zeaxanthin, vitamins C and E to quell oxidative stress.

18. Smoking‑Cessation Coaching (S) – Nicotine replacement plus behavioural therapy. Purpose: slows vascular damage that worsens retinal ischaemia. Mechanism: improves choroidal blood flow and antioxidant reserves.

19. Safe‑Home Environmental Audit (S) – Occupational‑therapist walkthrough installing tactile labels, high‑contrast stair edges. Purpose: fall and injury prevention. Mechanism: substitutes tactile and colour‑contrast cues for missing vision.

20. Self‑Monitoring Symptom Diary (S) – Daily log of floaters, flashes, blind‑spot size. Purpose: early relapse detection. Mechanism: empowers patient to recognise subtle progression before vision‑threatening spread.

---

Evidence‑Backed Antiviral Drugs

(Always check current local guidelines; dosing below reflects common adult regimens.)

1. Intravenous Ganciclovir – Class: nucleoside analogue DNA‑polymerase inhibitor. Dosage: 5 mg/kg IV every 12 h for 14‑21 days (induction), then 5 mg/kg IV daily (maintenance). Timing: start immediately after diagnosis. Side‑effects: neutropenia, anaemia, renal toxicity Medscape.

2. Oral Valganciclovir – Pro‑drug of ganciclovir with high bioavailability. Dosage: 900 mg orally twice daily for 21 days, then 900 mg once daily. Side‑effects: similar haematologic suppression but more convenient than IV.

3. Intravitreal Ganciclovir Implant (Vitrasert®) – Surgically placed polymer pellet. Dosage: releases ~1 µg/hour for 6‑8 months. Purpose: high intra‑ocular drug without systemic toxicity. Side‑effects: cataract, retinal detachment during placement American Academy of Ophthalmology.

4. Intravenous Foscarnet – Class: pyrophosphate analogue. Dosage: 60 mg/kg IV every 8 h (induction) then 90‑120 mg/kg IV daily. Side‑effects: nephrotoxicity, electrolyte imbalance; useful when ganciclovir resistance or bone‑marrow suppression occurs Medscape.

5. Intravenous Cidofovir – Dosage: 5 mg/kg IV once weekly × 2 weeks then every 2 weeks with probenecid nephro‑protection. Side‑effects: nephrotoxicity, uveitis, hypotony PMC.

6. Letermovir – Class: terminase‑complex inhibitor. Dosage: 480 mg orally once daily (or 240 mg with cyclosporine). While mainly approved for prophylaxis in transplant, emerging case‑reports show off‑label treatment for resistant CMV retinitis. Side‑effects: mild nausea, atrial fibrillation risk PMCTaylor & Francis Online.

7. Maribavir – Class: UL97 kinase inhibitor. Dosage: 400 mg orally twice daily for 8‑12 weeks. Effective against ganciclovir‑resistant strains; retinal cases documented in transplant recipients IC JournalIC Journal. Side‑effects: taste disturbance, diarrhoea.

8. Brincidofovir – Lipid‑conjugated cidofovir with lower renal toxicity. Dosage: 100 mg orally twice weekly in trials. Side‑effects: GI upset, elevated liver enzymes; still off‑label but promising for systemic CMV prophylaxis AstCT Journal.

9. CMV‑Specific Adoptive T‑Cell Therapy – Infusion of donor‑derived cytotoxic T‑cells primed against CMV pp65. Dosage: 1–2 × 10⁷ cells/m² intravenously, single or repeat. Side‑effects: transient fever; vision stabilisation reported in 80 % of treated eyes Retina TodayScienceDirect.

10. CMV Hyper‑Immune Globulin (CMV‑IG) – Concentrated IV immunoglobulin rich in anti‑CMV antibodies. Dosage: 150 mg/kg every 2 weeks adjunct to antivirals in transplant cases. Side‑effects: infusion reactions.

Key practice tip: Combining systemic (oral/IV) therapy with intravitreal injections or implants gives faster control of sight‑threatening lesions near the macula or optic nerve head.

---

Dietary Molecular Supplements

No pill can replace antivirals, but targeted nutrients dampen oxidative stress and support surviving retinal cells. The doses below reflect amounts used in Age‑Related Eye Disease Study (AREDS‑2) or typical clinical practice.

Practical note: Nutrients work best as part of a diet rich in dark‑green vegetables, fatty fish, nuts, and colourful fruit; pill overload can harm the liver or interact with antivirals.

---

Regenerative / Stem‑Cell‑Based Therapies

1. CMV‑Specific Cytotoxic T‑Cell Transfer – Already outlined above; it is a living‑cell drug that re‑populates CMV‑targeted immunity when antiviral resistance emerges Retina TodayOphthalmology Retina.

2. iPSC‑Derived RPE Patch – A lab‑grown sheet of patient‑specific retinal pigment cells placed sub‑retinally. Dosage: one 6 × 4 mm patch. Function: replaces scarred RPE, supporting photoreceptors. Mechanism: re‑establishes nutrient recycling; currently in early‑phase trials for geographic atrophy, but concept may extend to CMV scars.

3. Human Retinal Progenitor Cell (hRPC) Injection – Intravitreal suspension of 1 × 10⁶ progenitors (jCell®). Function: secretes neuro‑trophic factors to rescue borderline photoreceptors. Mechanism: paracrine neuro‑protection more than cell integration.

4. Mesenchymal Stem‑Cell Exosome Eye‑Drops – Topical nanoparticles carrying anti‑inflammatory micro‑RNA. Dosage: 50 µL tid for 8 weeks in pilot studies. Mechanism: dampens retinal microglial activation, potentially slowing scarring.

5. Gene‑Reprogramming Viral Vector (Mirugen Therapy) – Sub‑retinal AAV delivering transcription factors that convert Müller glia into new photoreceptors; pre‑clinical success in retinitis pigmentosa and AMD, expanding to infectious scars Herald Sun.

6. CRISPR‑Cas Anti‑CMV Editing – Ex‑vivo editing of autologous stem cells to knock‑out CMV immediate‑early gene promoter; reinfused cells resist future infection. Still theoretical but under investigation in mouse models.

Important: All six remain within phase I–II trials or compassionate‑use protocols; none replace standard antivirals yet. Discuss risks, costs, and trial eligibility with a specialist centre.

---

 Surgical Procedures

1. Pars Plana Vitrectomy (PPV) with Intravitreal Antiviral Infusion – Removes cloudy vitreous, allows direct drug bathing of retina, and facilitates laser barricade. Benefit: rapid clearing of dense floaters and delivery of high drug concentration.

2. Retinal Detachment Repair – Combination of PPV, endolaser, and silicone‑oil tamponade for CMV‑related holes. Benefit: re‑attaches retina, preserving residual vision.

3. Ganciclovir Implant Placement – Described above; counted as a surgical installation distinct from systemic therapy. Benefit: hands‑free maintenance drug for six months.

4. Laser Photocoagulation Barricade – Argon laser burns encircle an advancing lesion threatening macula. Benefit: creates adhesion, slowing spread into central vision.

5. Cataract Extraction in CMV Eyes – Cataracts accelerate with intravitreal steroids or implants; modern phaco surgery restores light and improves implant visualization.

---

Practical Prevention Strategies

1. Start ART promptly in HIV – Initiate within two weeks of anti‑CMV therapy to rebuild immunity EyeWiki.

2. Maintain CD4 > 100 cells/μL – Monitor counts; resume secondary prophylaxis if they drop.

3. Prophylactic Valganciclovir in Transplant – 900 mg daily for 3‑6 months in high‑risk serostatus.

4. Regular Dilated Fundus Exams – Every 3 months for CD4 < 100, monthly if < 50.

5. CMV PCR Monitoring in Blood – While predictive value is limited, some centres track viral load in transplant patients ClinicalInfo.

6. Safe Blood & Organ Screening – Use CMV‑negative or leukoreduced products when possible.

7. Hand‑Hygiene & Respiratory Etiquette – CMV spreads via saliva, urine, tears. Wash hands after diaper changes or nasal secretions.

8. Avoid Raw or Undercooked Meat – CMV can be present in pork products.

9. Use Barrier Contraception – Reduces sexual CMV exchange in discordant couples.

10. Healthy Lifestyle – No smoking, balanced diet, regular exercise to optimise immune system.

---

When Should You See a Doctor Urgently?

• New floaters like soot or cobwebs.

• Flashes of light or sudden curtain‑like shadow.

• Any drop in visual acuity, especially a “smeared” central spot.

• Peripheral field loss you can trace with hand movement.

• Persistent eye pain or redness after intravitreal injection.

• Fever or malaise while on antivirals (possible drug toxicity or resistant CMV).

---

Things to Do – and Ten to Avoid

Do

1. Take antivirals exactly on schedule.

2. Keep every follow‑up dilated eye exam.

3. Use sunglasses outdoors to cut retinal oxidative stress.

4. Eat dark‑green leafy vegetables and oily fish twice a week.

5. Set phone alarms for medication and appointment reminders.

6. Practise the eye‑movement exercises listed above daily.

7. Report new symptoms immediately.

8. Store valganciclovir in a cool, dry place.

9. Wear protective eyewear if working with sharp tools.

10. Share emotional concerns with peer groups or counsellors.

Avoid

1. Stopping antivirals early because vision “looks fine.”

2. Missing ART doses (HIV viral rebound fuels CMV).

3. Smoking or vaping.

4. Excess alcohol that strains the liver on antivirals.

5. High‑dose vitamin A if pregnant (teratogenic).

6. Over‑the‑counter steroids without ophthalmologist approval.

7. Driving at night during active disease without clearance.

8. Eye rubbing – increases retinal detachment risk.

9. Unverified herbal “cures” that may delay proven therapy.

10. Sharing eye‑drops – cross‑infection risk.

---

Frequently Asked Questions (FAQs)

1. Can CMV retinitis heal on its own?
   No. Without antiviral therapy the virus replicates unchecked, destroying retinal cells permanently.

2. How long will I need treatment?
   Induction lasts 2‑3 weeks; maintenance continues until your immune system recovers (CD4 > 100 for 3‑6 months) or until transplant immunosuppression is tapered.

3. Will one eye medicine protect the other eye?
   Systemic (oral or IV) drugs treat both eyes; local injections only treat the injected eye.

4. Is letremovir safer than ganciclovir?
   Letermovir causes far less bone‑marrow suppression but does not yet have full approval for ocular disease; it is mainly for resistant or prophylactic cases PMC.

5. Why did my doctor delay ART by two weeks?
   Starting ART too early can trigger immune‑reconstitution inflammatory syndrome (IRIS) that paradoxically worsens retinal inflammation.

6. What is IRIS and will it blind me?
   IRIS is an over‑vigorous immune rebound. It can add swelling but rarely causes blindness if monitored; short‑course steroids may be used.

7. Can I get CMV retinitis again after successful treatment?
   Yes, relapse occurs if immunity drops or if resistant CMV emerges, hence the need for maintenance dosing and regular exams.

8. Is eye surgery risky in CMV patients?
   With modern vitrectomy, complication rates are low; delaying surgery when indicated often leads to worse outcomes.

9. Do blue‑light‑filter glasses help?
   They can reduce glare and oxidative stress but are not a substitute for drug therapy.

10. Are dietary supplements necessary if I eat well?
    Most nutrients can be obtained from diet, but targeted replacement following AREDS‑2 may benefit those with poor intake; discuss with your clinician NCCIH.

11. Can children get CMV retinitis?
    Congenital CMV can cause retinal scarring at birth, but active CMV retinitis is rare outside severe paediatric immunosuppression.

12. Is CMV contagious through casual contact?
    CMV spreads via close bodily fluid contact; normal social interaction poses minimal risk to healthy adults.

13. Do antivirals affect fertility?
    High‑dose ganciclovir can reduce sperm count temporarily; pregnancy planning should be discussed beforehand.

14. What if I miss a valganciclovir dose?
    Take it as soon as you remember unless your next dose is due in < 4 hours; never double dose.

15. Will future stem‑cell therapies make antivirals obsolete?
    Unlikely in the near term. Regenerative options aim to restore structure after infection but do not control active virus, so antivirals will remain first‑line.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 17, 2025.